New molecular diagnostics business launched in Manchester
The aim of APIS Assay Technologies is to help to realise the clinical and commercial potential of genomic medicine in diagnostic tests and personalisation of treatment.
Read More
Author: Anna Smith
Zolgensma wins FDA green light in child SMA
The $2.1 milllion per treatment price tag has garnered substantial criticism.
Read More
Final NICE guidance issued for Akcea’s Tegsedi
The drug should be available for routine use within 90 days for patients in England.
Read More
GSK updates its sales rep incentives
The company implemented stricter rules in 2012 as part of a broad transparency initiative.
Read More
NHS to undergo ‘ambitious’ tech overhaul
In the past three months alone, the NHS has prevented more than 21 million potential cyber attacks.
Read More- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
